Neuraxis, Inc. NRXS 深 滬
交易中 11-03 10:13:38 美东时间
2.67
-0.050
-1.84%
華盛通- 最 高2.70
- 今 開2.72
- 成交量 1.74万股
- 最 低 2.67
- 昨 收 2.72
- 總市值 2636.04万
- 52周最高 6.20
- 市盈率 靜 --
- 換手率 0.18%
- 52周最低 1.33
- 委 比 -81.82%
- 總股本 987.28万
- 歷史最高 6.93
- 量 比 0.74
- 振 幅 1.10%
- 歷史最低 1.33
- 每 手 1
- 風險率 0.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NeurAxis Expands Stock Offering to $6.27 Million
NeurAxis, Inc. ( ($NRXS) ) has issued an announcement. NeurAxis, Inc. has recei...
10-24 20:48
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population
NeurAxis has received FDA clearance for its PENFS technology to treat functional abdominal pain and nausea in patients aged 8 and older, marking the first FDA-approved treatment for adults with functional dyspepsia. This expansion includes a new CPT code effective January 1, 2026, enhancing its market reach and offering a non-invasive solution for patients with limited treatment options.
10-24 12:00
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress
Nurix Therapeutics announced clinical data from the Phase 1a study of NX-1607, a first-in-class oral CBL-B inhibitor for treating advanced solid tumors. NX-1607 showed on-target immune activation and anti-tumor activity, including tumor biomarker reductions, tumor shrinkage, and partial responses in heavily pretreated patients. Results from 82 patients across 11 tumor types demonstrated dose-dependent activity, with a 49.3% disease control rate. ...
10-18 07:00
NeurAxis Enters Market Offering Agreement with Craig-Hallum
NeurAxis, Inc. ( ($NRXS) ) has provided an update. On August 29, 2025, Neuraxis...
09-02 21:52
Neuraxis Q2 EPS $(0.22) Beats $(0.23) Estimate, Sales $894.086K Miss $967.250M Estimate
Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.35 percent. This is a 47.62 percent increase over losses of $(0.42) per share from the same
08-12 19:05
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues
NeurAxis Inc. reported 2Q25 financial results with a 46% YoY revenue increase to $894K, operating expenses down 10% YoY, and a 22% improvement in operating loss. The company secured FDA clearance for expanded uses of its IB-Stim therapy for pediatric conditions and received a new CPT code for 2026. Cash balance reached $6M following a $5M equity融资 round. With strong unit sales growth and expanded insurance coverage, NeurAxis remains confident in ...
08-12 11:00
Earnings Outlook For Neuraxis
Neuraxis (AMEX:NRXS) is preparing to release its quarterly earnings on Tuesday,...
08-12 02:03
NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025
NeurAxis, Inc. will release its second quarter 2025 financial results on August 12, 2025, before market open. A conference call will be held at 9:00 am ET on the same day to discuss the results. The event will be webcast live and available for replay on the Company's Investor Relations website. NeurAxis specializes in neuromodulation therapies for chronic conditions in children and adults, with its IB-Stim™ therapy cleared by the FDA for function...
08-05 12:30
NeurAxis, Inc. Ends Agreement with Masimo Corporation
NeurAxis, Inc. ( ($NRXS) ) has provided an announcement. On July 1, 2025, NeurA...
07-04 01:47
